BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

634 related articles for article (PubMed ID: 16734503)

  • 1. Management of refractory early-stage cutaneous T-cell lymphoma.
    Huber MA; Staib G; Pehamberger H; Scharffetter-Kochanek K
    Am J Clin Dermatol; 2006; 7(3):155-69. PubMed ID: 16734503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of cutaneous T cell lymphoma: current status and future directions.
    Apisarnthanarax N; Talpur R; Duvic M
    Am J Clin Dermatol; 2002; 3(3):193-215. PubMed ID: 11978140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms.
    Duvic M
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S51-5. PubMed ID: 11707865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.
    Duvic M
    Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):33-40. PubMed ID: 17474358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical and systemic retinoid therapy for cutaneous T-cell lymphoma.
    Kempf W; Kettelhack N; Duvic M; Burg G
    Hematol Oncol Clin North Am; 2003 Dec; 17(6):1405-19. PubMed ID: 14710892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous T cell lymphoma: update of treatment.
    Zackheim HS
    Dermatology; 1999; 199(2):102-5. PubMed ID: 10559573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal combination with PUVA: rationale and clinical trial update.
    Stadler R
    Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):29-32. PubMed ID: 17474357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current management strategies for cutaneous T-cell lymphoma.
    Knobler E
    Clin Dermatol; 2004; 22(3):197-208. PubMed ID: 15262305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracorporeal photophoresis: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic alternatives in cutaneous T-cell lymphoma.
    Holloway KB; Flowers FP; Ramos-Caro FA
    J Am Acad Dermatol; 1992 Sep; 27(3):367-78. PubMed ID: 1383293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bexarotene gel: a new skin-directed treatment option for cutaneous T-cell lymphomas.
    Martin AG
    J Drugs Dermatol; 2003 Apr; 2(2):155-67. PubMed ID: 12852367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bexarotene in the treatment of cutaneous T-cell lymphoma.
    Querfeld C; Nagelli LV; Rosen ST; Kuzel TM; Guitart J
    Expert Opin Pharmacother; 2006 May; 7(7):907-15. PubMed ID: 16634713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of phototherapy in cutaneous T-cell lymphoma.
    Pothiawala SZ; Baldwin BT; Cherpelis BS; Lien MH; Fenske NA
    J Drugs Dermatol; 2010 Jul; 9(7):764-72. PubMed ID: 20677530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
    Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
    Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
    Kannangara AP; Levitan D; Fleischer AB
    J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Choices in the treatment of cutaneous T-cell lymphoma.
    Hymes KB
    Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):18-23. PubMed ID: 17474355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of the primary cutaneous lymphomas.
    Prince HM; McCormack C; Ryan G; O'Keefe R; Seymour JF; Baker C
    Australas J Dermatol; 2003 Nov; 44(4):227-40; quiz 241-2. PubMed ID: 14616487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and emerging treatment strategies for cutaneous T-cell lymphoma.
    Lansigan F; Foss FM
    Drugs; 2010 Feb; 70(3):273-86. PubMed ID: 20166766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on treatment of cutaneous T-cell lymphoma.
    Gardner JM; Evans KG; Musiek A; Rook AH; Kim EJ
    Curr Opin Oncol; 2009 Mar; 21(2):131-7. PubMed ID: 19532014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.